Clinical trials: Parkinson
Idiopathic Parkinson Disease
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients
This is a prospective study in a cohort of about 500 patients with Idiopathic Parkinson's disease, examined routinely in the neurological outpatient clinic.
- Trial name
- NCT05437003
- Testing
- NeuraLight software-based platform
- Where
- Israel
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- NeuraLight
Parkinson's Disease
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder…
- Trial name
- NCT03703570
- Testing
- KW-6356
- Where
- Japan
- Volunteers
- 502 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as…
- Trial name
- NCT02172573
- Testing
- Pramipexole, Bromocriptine
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Healthy
A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions
This study is designed to evaluate the safety and plasma concentrations of PF-06669571 in healthy volunteers following single and multiple ascending doses of PF-06669571.
- Trial name
- NCT02184429
- Testing
- PF-06669571
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pfizer
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
In this study, participants with previously-treated locally-advanced unresectable or metastatic mismatched repair (MMR) deficient or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) will be treated with…
- Trial name
- NCT02460198
- Testing
- Pembrolizumab
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease Psychosis
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).
- Trial name
- NCT05344365
- Testing
- Iloperidone
- Where
- United States
- Sponsor
- Vanda Pharmaceuticals
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not…
- Trial name
- NCT03834493
- Testing
- Pembrolizumab, Enzalutamide
- Where
- 259 sites in United States, Argentina and 26 more
- Volunteers
- 1,244 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease
This clinical trial focus on the delivery of Cerezyme® in Parkinson's Disease (PD) patients using MR-guided focused ultrasound (MRgFUS) induced opening of the blood-brain barrier (BBB).
- Trial name
- NCT04370665
- Testing
- Exablate BBBD with Cerezyme
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Parkinson Disease, Dyskinesia, Medication-Induced
Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia
The aim of the study is to determine potential anti-dyskinetic properties of CPL500036 (PDE10A inhibitor) in Parkinson disease patients suffering from levodopa Induced dyskinesia.
- Trial name
- NCT05297201
- Testing
- CPL500036 - low dose, CPL500036 - high dose
- Where
- 16 sites in Poland, Ukraine
- Volunteers
- 105 people
- Sponsor
- Celon Pharma SA
Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after…
- Trial name
- NCT03976375
- Testing
- Pembrolizumab, Lenvatinib, Docetaxel
- Where
- 143 sites in United States, Argentina and 16 more
- Volunteers
- 422 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease, Parkinson Disease
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa…
- Conditions
- Parkinson's Disease, Parkinson Disease, Dyskinesias
- Trial name
- NCT00363727
- Testing
- ropinirole controlled-release (REQUIP CR) for RLS
- Where
- 69 sites in United States
- Volunteers
- 209 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Parkinson Disease
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
Study to assess and compare the safety of long term oral treatment for Parkinson's Disease with pramipexole versus bromocriptine or other dopamine agonists, by measuring cross-sectional the incidence of ophthalmologic…
- Trial name
- NCT02233023
- Testing
- Pramipexole, Bromocriptine and other dopamine agonists
- Volunteers
- 705 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been…
- Trial name
- NCT04165096
- Testing
- Pembrolizumab, Boserolimab, MK-4830
- Where
- 39 sites in United States, Hungary and 5 more
- Volunteers
- 128 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
- Trial name
- NCT07219927
- Testing
- Observational study
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson Disease
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease
- Trial name
- NCT04691661
- Testing
- Radotinib HCl 50 mg
- Where
- 7 sites in France
- Volunteers
- 43 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Parkinson´s Disease
Rostock International Parkinson's Disease Study (ROPAD)
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the…
- Trial name
- ROPAD (NCT03866603)
- Where
- 110 sites in United States, Albania and 13 more
- Volunteers
- 20,112 people
- Sponsor
- CENTOGENE GmbH Rostock
Parkinson's Disease
Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease
The primary objectives of the trial are to assess the safety and efficacy of ProSavin. Patients in the trial will have been diagnosed with Parkinson's disease and will be failing on current treatment with L-DOPA but they will not…
- Trial name
- NCT00627588
- Testing
- ProSavin
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Oxford BioMedica
Melanoma
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with…
- Trial name
- NCT02027961
- Testing
- Durvalumab, Dabrafenib, Trametinib
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.